Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.
Official title: A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
79
Start Date
2025-09-25
Completion Date
2026-03-31
Last Updated
2025-12-31
Healthy Volunteers
Yes
Conditions
Interventions
IBI3032
IBI3032. Method of administration: oral, fasted administration.
placebo
Placebo (without active ingredients). Method of administration: oral, fasted administration.
Locations (1)
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China